News Feature
Nature Biotechnology 25, 707 - 709 (2007)
Published online: 2 July 2007 | doi:10.1038/nbt0707-707
Bad medicine
Cormac Sheridan1
- Dublin, Ireland
Abstract
As more high-ticket biologic drugs reach the marketplace, the biotech industry may be increasingly beset by counterfeiters. Do regulators and law enforcement have the tools they need?

